


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-24. (Canceled)

25. (Currently Amended) A compound according to the formula IA:



IA

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof,
wherein

D is absent or selected from the group consisting of

- (1) substituted or unsubstituted C₃-C₈-cycloalkyl;
- (2) substituted or unsubstituted aryl;
- (3) substituted or unsubstituted heterocyclyl; and
- (4) substituted or unsubstituted heteroaryl;

Y is selected from the group consisting of

- (1) substituted or unsubstituted C₃-C₈-cycloalkyl;
- (2) ~~substituted or unsubstituted aryl;~~
- (3) ~~substituted or unsubstituted~~ heterocyclyl; and
- (3) (4) ~~substituted or unsubstituted~~ heteroaryl;

R₄ is H or substituted or unsubstituted C₁-C₆-alkyl;

A is selected from the group consisting of

(1) $-\text{C}(\text{R}^{1a}, \text{R}^{2a})\text{OR}^{3a}$; and

(2) $-\text{C}(\text{R}^{1a}, \text{R}^{2a})\text{N}(\text{R}^{4a}, \text{R}^{5a})$;

wherein R^{1a} , R^{2a} , R^{3a} , R^{4a} , and R^{5a} are independently selected from the group consisting of

(1) H; and

(2) substituted and unsubstituted C_1 - C_6 -alkyl.


26. (Previously Presented) The compound of claim 25, wherein A is $-\text{C}(\text{R}^{1a}, \text{R}^{2a})\text{OR}^{3a}$.

27. (Previously Presented) The compound of claim 26, wherein A is $-\text{CH}_2\text{OH}$.

28. (Previously Presented) The compound of claim 26, wherein A is $-\text{CH}(\text{CH}_3)\text{OH}$.

29-33. (Canceled).

34. (Currently Amended) A compound according to the formula IB:



IB

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof,

wherein

D is absent or selected from the group consisting of

(1) substituted or unsubstituted C_3 - C_8 -cycloalkyl;

(2) substituted or unsubstituted aryl;

(3) substituted or unsubstituted heterocyclyl; and

(4) substituted or unsubstituted heteroaryl;

G is $-\text{C}\equiv\text{C}-\text{C}\equiv\text{C}-$;

Y is selected from the group consisting of

- (1) substituted or unsubstituted C₃-C₈-cycloalkyl;
- (2) substituted or unsubstituted aryl;
- (3) substituted or unsubstituted heterocyclyl; and
- (4) substituted or unsubstituted heteroaryl;

R₄ is H or substituted or unsubstituted C₁-C₆-alkyl;


A is $-\text{C}(\text{R}^{1a}, \text{R}^{2a})\text{N}(\text{R}^{4a}, \text{R}^{5a})$;

wherein R^{1a}, R^{2a}, [[R^{3a},]] R^{4a}, and R^{5a} are independently selected

from the group consisting of

- (1) H; and
- (2) substituted and unsubstituted C₁-C₆-alkyl.

35. (Previously Presented) A compound according to Formula VIII:



VIII

or stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, wherein

E is absent or selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C₁-C₆-alkyl,
- (3) substituted or unsubstituted aryl,

(4) substituted or unsubstituted heterocyclyl, and

(5) substituted or unsubstituted heteroaryl,

or E and R^{3L}, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S;

R^{1L}, R^{3L} are independently selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C₁-C₆-alkyl,


(3) C₁-C₆-alkyl substituted with aryl,

(4) C₁-C₆-alkyl substituted with heterocyclyl, and

(5) C₁-C₆-alkyl substituted with heteroaryl,

or R^{1L} and R^{3L}, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 7 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

36. (Previously Presented) A compound of claim 34 according to Formula IX:



IX

or stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, wherein

E is absent or selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C₁-C₆-alkyl,
- (3) substituted or unsubstituted aryl,
- (4) substituted or unsubstituted heterocyclyl, and
- (5) substituted or unsubstituted heteroaryl,


or E and R^{3L}, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S;

R^{1L}, R^{3L} are independently selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C₁-C₆-alkyl,
- (3) C₁-C₆-alkyl substituted with aryl,
- (4) C₁-C₆-alkyl substituted with heterocyclyl, and
- (5) C₁-C₆-alkyl substituted with heteroaryl,

or R^{1L} and R^{3L}, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 7 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

37. (Previously Presented) A compound of claim 34 according to Formula X:



X

or stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, wherein E is absent or selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C₁-C₆-alkyl,
- (3) substituted or unsubstituted aryl,
- (4) substituted or unsubstituted heterocyclyl, and
- (5) substituted or unsubstituted heteroaryl,

or E and R^{3L}, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S;

R^{1L}, R^{3L} are independently selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C₁-C₆-alkyl,
- (3) C₁-C₆-alkyl substituted with aryl,
- (4) C₁-C₆-alkyl substituted with heterocyclyl, and
- (5) C₁-C₆-alkyl substituted with heteroaryl,

or R^{1L} and R^{3L}, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 7 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

38. (Previously Presented) A pharmaceutical composition comprising the compound of claim 25 and a pharmaceutically acceptable excipient.

39. (Previously Presented) A pharmaceutical composition comprising the compound of claim 34 and a pharmaceutically acceptable excipient.

40. (Previously Presented) A pharmaceutical composition comprising a compound of claim 25, a second agent, and a pharmaceutically acceptable excipient, wherein the

second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

41. (Previously Presented) A pharmaceutical composition comprising a compound of claim 34, a second agent, and a pharmaceutically acceptable excipient, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

42. (Previously Presented) A method of inhibiting LpxC comprising administering to a patient in need thereof, an effective amount of the compound of claim 25.

43. (Previously Presented) A method of inhibiting LpxC comprising administering to a patient in need thereof, an effective amount of the compound of claim 34.

44. (Previously Presented) A method of inhibiting LpxC comprising administering to a patient in need thereof, an effective amount of the compound of claim 25 and an effective amount of a second agent, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

45. (Previously Presented) A method of inhibiting LpxC comprising administering to a patient in need thereof, an effective amount of the compound of claim 34 and an effective amount of a second agent, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.


46. (Previously Presented) A method of treating an infection comprising administering to a patient in need thereof, an effective amount of the compound of claim 25.

47. (Previously Presented) A method of treating an infection comprising administering to a patient in need thereof, an effective amount of the compound of claim 34.

48. (Previously Presented) A method of treating an infection comprising administering to a patient in need thereof, an effective amount of the compound of claim 25 and an effective amount of a second agent, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

49. (Previously Presented) A method of treating an infection comprising administering to a patient in need thereof, an effective amount of the compound of claim 34 and an effective amount of a second agent, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

50. (New) A compound according to the formula IA:



IA

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof,
wherein

D is absent or selected from the group consisting of

- (1) substituted or unsubstituted C₃-C₈-cycloalkyl;
- (2) substituted or unsubstituted aryl;
- (3) substituted or unsubstituted heterocyclyl; and
- (4) substituted or unsubstituted heteroaryl;

Y is selected from the group consisting of

- (1) substituted or unsubstituted aryl;
- (2) substituted or unsubstituted heterocyclyl; and
- (3) substituted or unsubstituted heteroaryl;

R_4 is H or substituted or unsubstituted C_1 - C_6 -alkyl;

A is $-C(R^{1a}, R^{2a})N(R^{4a}, R^{5a})$;

wherein R^{1a} , R^{2a} , R^{4a} , and R^{5a} are independently selected from the group consisting of

- (1) H; and
- (2) substituted and unsubstituted C_1 - C_6 -alkyl.


51. (New) The compound of claim 50, wherein A is $-CH_2NH_2$.

52. (New) The compound of claim 50, wherein A is $-CH(CH_3)NH_2$.

53. (New) The compound of claim 50, wherein D is absent and Y is a substituted or unsubstituted aryl.

54. (New) The compound of claim 50, wherein D is a substituted or unsubstituted aryl and Y is a substituted or unsubstituted aryl.

55. (New) A compound according to the formula IA:



IA

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof,

wherein

D is absent or selected from the group consisting of

- (1) substituted or unsubstituted C₃-C₈-cycloalkyl;
- (2) substituted or unsubstituted aryl;
- (3) substituted or unsubstituted heterocyclyl; and
- (4) substituted or unsubstituted heteroaryl;

Y is an unsubstituted aryl;


R₄ is H or substituted or unsubstituted C₁-C₆-alkyl; and

A is -CH₂OH.

56. (New) The compound of claim 55, wherein D is absent.

57. (New) The compound of claim 55, wherein D is a substituted or unsubstituted aryl.

58. (New) A compound according to the formula IA:



IA

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof,

wherein

D is absent or selected from the group consisting of

- (1) substituted or unsubstituted C₃-C₈-cycloalkyl;
- (2) substituted or unsubstituted aryl;
- (3) substituted or unsubstituted heterocyclyl; and
- (4) substituted, or unsubstituted heteroaryl;

Y is selected from the group consisting of

- (1) substituted or unsubstituted aryl; and
- (2) unsubstituted heterocyclyl; and
- (3) unsubstituted heteroaryl;


R₄ is H or substituted or unsubstituted C₁-C₆-alkyl; and

A is -CH(CH₃)OH.

59. (New) The compound of claim 58, wherein D is absent and Y is a substituted or unsubstituted aryl.

60. (New) The compound of claim 58, wherein D is a substituted or unsubstituted aryl and Y is a substituted or unsubstituted aryl.

61. (New) A compound according to the formula IA:



IA

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof,
wherein

D is selected from the group consisting of

- (1) substituted or unsubstituted C₃-C₈-cycloalkyl;
- (2) substituted or unsubstituted aryl;
- (3) substituted or unsubstituted heterocyclyl; and
- (4) substituted or unsubstituted heteroaryl;

Y is selected from the group consisting of

- (1) substituted or unsubstituted C₃-C₈-cycloalkyl;
- (2) substituted or unsubstituted aryl;
- (3) substituted or unsubstituted heterocyclyl; and
- (4) substituted or unsubstituted heteroaryl;

R₄ is H or substituted or unsubstituted C₁-C₆-alkyl;

A is selected from the group consisting of

- (1) -C(R^{1a}, R^{2a})OR^{3a}; and
- (2) -C(R^{1a}, R^{2a})N(R^{4a}, R^{5a});

wherein R^{1a}, R^{2a}, R^{3a}, R^{4a}, and R^{5a} are independently selected from the group consisting of

- (1) H; and
- (2) substituted and unsubstituted C₁-C₆-alkyl.

62. (New) A pharmaceutical composition comprising the compound of any one of claims 35, 50, 55, 58 or 61 and a pharmaceutically acceptable excipient.

63. (New) A pharmaceutical composition comprising a compound of any one of claims 35, 50, 55, 58 or 61, a second agent, and a pharmaceutically acceptable excipient, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

64. (New) A method of inhibiting LpxC comprising administering to a patient in need thereof, an effective amount of the compound of any one of claims 35, 50, 55, 58 or 61.

65. (New) A method of inhibiting LpxC comprising administering to a patient in need thereof, an effective amount of the compound of any one of claims 35, 50, 55, 58 or 61, and an effective amount of a second agent, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

66. (New) A method of treating an infection comprising administering to a patient in need thereof, an effective amount of the compound of any one of claims 35, 50, 55, 58 or 61.

67. (New) A method of treating an infection comprising administering to a patient in need thereof, an effective amount of the compound of any one of claims 35, 50, 55, 58, or 61 and an effective amount of a second agent, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.